Special considerations for treatment of type 2 diabetes mellitus in the elderly

American Journal of Health-System Pharmacy

Volumn 68, Issue 6, 2011, Pages 500-509

  Fravel, Michelle A ^a   McDanel, Deanna L ^a,b   Ross, Mary B ^b,c   Moores, Kevin G ^d   Starry, Mary J ^b  

^a UNIVERSITY OF IOWA   (United States)

^b Department of Pharmacy Practice   (United States)

^c UIHC   (United States)

^d Drug Information Service   (United States)

Author keywords

Antidiabetic agents; Chlorpropamide; Diabetes mellitus; Drug interactions; Drugs; Geriatrics; Glyburide; Hypoglycemia; Rational therapy; Rosiglitazone; Toxicity

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; CHLORPROPAMIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; INDAPAMIDE PLUS PERINDOPRIL; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; UNINDEXED DRUG;

AGE DISTRIBUTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DISEASE PREDISPOSITION; DRUG FATALITY; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GERIATRIC PATIENT; GLYCEMIC CONTROL; HEALTH CARE QUALITY; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN TREATMENT; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; LACTIC ACIDOSIS; MACROVASCULAR DISEASE; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYPHARMACY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINOPATHY; REVIEW; RISK ASSESSMENT; SELF MONITORING; SIDE EFFECT; TREATMENT CONTRAINDICATION; VASCULAR DISEASE;

EID: 79956043339     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp080085     Document Type: Review

References (70)

1. Centers for Disease Control and Prevention. Diabetes data and trends. http://apps.nccd.cdc.gov/ddtstrs (accessed 2010 Jan 15).
2. Centers for Disease Control and Prevention. Number of people with diabetes increases to 24 million. www.cdc.gov/media/pressrel/2008/r080624.htm (accessed 2010 Jan 15).
3. Boyle JP, Honeycutt AA, Narayan KM et al. Projection of diabetes burden through 2050. Diabetes Care. 2001; 24:1936-40.
4. Brown AF, Mangione CM, Saliba D et al. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc. 2003; 51(suppl):S265-80.
5. Smith NL, Savage PJ, Heckbert SR et al. Glucose, blood pressure, and lipid control in older people with and without diabetes mellitus: the cardiovascular health study. J Am Geriatr Soc. 2002; 50:416-23. (Pubitemid 34229394)
6. Harris MI. Medical care for patients with diabetes: epidemiological aspects. Ann Intern Med. 1996; 1241:117-22. (Pubitemid 26011607)
7. Weiner JP, Parente ST, Garnick DW et al. Variation in office-based quality: a claims-based profile of care provided to Medicare patients with diabetes. JAMA. 1995; 273:1503-8.
8. Blaum CS. Management of diabetes mellitus in older adults: are national guidelines appropriate? J Am Geriatr Soc. 2002; 50:581-3.
9. Lecomte P. Diabetes in the elderly: considerations for clinical practice. Diabetes Metab. 2005; 31:5S103-9.
10. Bauduceau B, Bourdel-Marchasson I, Brocker P et al. The brain of the elderly diabetic patient. Diabetes Metab. 2005; 31:5S92-7.
11. Nelson JM, Dufraux K, Cook PF. The relationship between glycemic control and falls in older adults. J Am Geriatr Soc. 2007; 49:1-4.
12. Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358:2560-72. (Pubitemid 351831357)
13. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360:129-39.
14. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358:2545-59. (Pubitemid 351831356)
15. Booth GL, Kapral MK, Fung K et al. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet. 2006; 368:29-36. (Pubitemid 43947203)
16. Abraira C, Colwell JA, Nuttall F et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial: Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med. 1997; 157:181-8. (Pubitemid 27058152)
17. Chew EY, Ambrosius WT, Davis MD et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010; 363:233-44.
18. United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837-53.
19. Holman RR, Paul SK, Bethel MA et al. 10- year followup of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359:1577-89.
20. American Diabetes Association. Standards of medical care in diabetes - 2011. Diabetes Care. 2011; 34(suppl):S11-61.
21. Rodbard HW, Jellinger PS, Davidson JA et al. Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009; 15:540-59.
22. Fick DM, Cooper JW, Wade WE et al. Updating the Beers criteria for potentially inappropriate medication use in older adults. Arch Intern Med. 2003; 163:2716-24. (Pubitemid 37517412)
23. Snyder R, Berns J. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial. 2004; 17:365-70. (Pubitemid 39422090)
24. Rydberg T, Johnson A, Roder M et al. Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care. 1994; 17:1026-30. (Pubitemid 24268615)
25. Krepinsky J, Ingram A, Clase C. Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis. 2000; 35:500-5.
26. Holstein A, Egberts EH. Risk of hypoglycaemia with oral antidiabetic agents in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2003; 111:405-14. (Pubitemid 37486432)
27. Holstein A, Plaschke A, Hammer C et al. Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycemia. Eur J Clin Pharmacol. 2003; 59:91-7. (Pubitemid 36793719)
28. Charpentier G, Riveline JP, Varroud- Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab. 2000; 26:73-85. (Pubitemid 30618360)
29. Rosenstock J, Corrao PJ, Goldberg R et al. Diabetes control in the elderly: a randomized, comparative study of glyburide versus glipizide in non-insulindependent diabetes mellitus. Clin Ther. 1993; 15:1031-40. (Pubitemid 24045905)
30. Brodows R. Benefits and risks with glyburide in elderly NIDDM patients. Diabetes Care. 1992; 15:75-80.
31. Dills D, Schneider J. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Horm Metab Res. 1996; 28:426-9. (Pubitemid 26343732)
32. Del Prato S, Heine R, Keilson L et al. Treatment of patients over 64 years of age with type 2 diabetes. Diabetes Care. 2003; 26:2075-80.
33. Jones GC, Macklin JP, Alexander WD. Contraindications to the use of metformin. BMJ. 2003; 326:4-5. Editorial.
34. Nisbet JC, Sturtevant JM, Prins JB. Metformin and serious adverse effects. Med J Aust. 2004; 180:53-4. Editorial.
35. Herrington WG, Levy JB. Metformin: effective and safe in renal disease? Int Urol Nephrol. 2008; 50:411-7.
36. Philbrick AM, Ernst ME, McDanel DL et al. Metformin use in renal dysfunction: is a serum creatinine threshold appropriate? Am J Health-Syst Pharm. 2009; 66:2017-23.
37. Glucophage (metformin) prescribing information. Laval, Quebec: Sanofi-Aventis Canada; 2006 Jun.
38. Inzucchi SE. The stealth label change. http://docnews.diabetesjournals. org/ cgi/content/full/4/12/2 (accessed 2010 Jul 19).
39. Glucophage (metformin) prescribing information. Princeton, NJ: Bristol-Myers Squibb; 2009 Jan.
40. Roberts F, Ryan GJ. The safety of metformin in heart failure. Ann Pharmacother. 2007; 41:642-6. (Pubitemid 46625487)
41. Salpeter S, Greyber E, Pasternak G et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2006; 1:CD002967.
42. Actos (pioglitazone hydrochloride) package insert. Deerfield, IL: Takeda Pharmaceuticals America; 2009.
43. Avandia (rosiglitazone maleate) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2008.
44. Nesto RW, Bell D, Bonow RO et al. Thiazolidinedione use, fluid retention, and congestive heart failure. Diabetes Care. 2004; 27:256-63.
45. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356:1-15.
46. Nissen SE, Wolsky K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. Epub ahead of print. 2010 Jun 28 (DOI 10.1001/ archinternmed.2010.207).
47. Graham DJ, Ouellet-Hellstrom R, McCurdy TE et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010; 304:E1-8.
48. Food and Drug Administration. Postmarket drug safety information for patients and providers. www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafety InformationforPatientsandProviders/ ucm226956.htm (accessed 2011 Jan 12).
49. Riche DM, King ST. Bone loss and fracture risk associated with thiazolidinedione therapy. Pharmacotherapy. 2010; 30:716-27.
50. Viberti G, Kahn SE, Greene DA et al. A Diabetes Outcome Progression Trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care. 2002; 25:1737-43. (Pubitemid 41071079)
51. Kahn SE, Zinman C, Lachin MM et al. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008; 31:845-51.
52. Papa G, Fedele V, Rizzo MR et al. Safety of type 2 diabetes treatment with repaglinide compared with glibenclamide in elderly people. Diabetes Care. 2006; 29:1918-20.
53. Nathan DM, Buse JB, Mayer DB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2009; 32:193-203.
54. Josse R, Chiasson E, Ryan E et al. Acarbose in the treatment of elderly patients with type 2 diabetes. Diabetes Res Clin Pract. 2003; 59:37-42. (Pubitemid 35461908)
55. Greco D, Angileri G. Drug-induced severe hypoglycaemia in type 2 diabetic patients aged 80 years or older. Diabetes Nutr Metab. 2004; 17:23-6. (Pubitemid 38578514)
56. Symlin (pramlintide acetate) package insert. San Diego, CA: Amylin Pharmaceuticals; 2008.
57. Januvia (sitagliptin) package insert. Whitehouse Station, NJ: Merck and Co.; 2009.
58. Onglyza (saxagliptin) package insert. Princeton, NJ: Bristol-Myers Squibb; 2009.
59. Byetta (exenatide) package insert. San Diego, CA: Amylin Pharmaceuticals; 2009.
60. Victoza (liraglutide) package insert. Bagsvaerd, Denmark: Novo Nordisk; 2010.
61. Amylin Pharmaceuticals. Exenatide once weekly. www.amylin.com/research/ pipeline/exenatide.htm (accessed 2010 Jul 19).
62. United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ. 1998; 317:703-13.
63. Haffner SM, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339:229-34. (Pubitemid 28350165)
64. Grover S, Coupal L, Zowall H et al. Cost-effectiveness of treating hyperlipidemia in the presence of diabetes: who should be treated? Circulation. 2000; 102:722-7.
65. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003; 289:2560-72. (Pubitemid 37430158)
66. Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008; 358:1887-98. (Pubitemid 351620109)
67. Rosendorff C, Black HR, Cannon CP et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association council for high blood pressure research and the councils on clinical cardiology and epidemiology and prevention. Circulation. 2007; 115:2761-88. (Pubitemid 46842793)
68. Ogawa H, Nakayama M, Morimoto T et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008; 300:2134-41.
69. Belch J, MacCuish A, Campbell I et al. The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008; 337:a1840.
70. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285:2486-97.